Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy

The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors and protease inhibitors provide a framework for the implementation of TDM in certain defined scenarios in clinical...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2005-01, Vol.10 (3), p.375-392
Main Authors: BOFFITO, Marta, ACOSTA, Edward, REGAZZI, Mario, BACK, David, BURGER, David, FLETCHER, Courtney V, FLEXNER, Charles, GARAFFO, Rodolphe, GATTI, Giorgio, KUROWSKI, Michael, PERNO, Carlo Federico, PEYTAVIN, Gilles
Format: Article
Language:English
Subjects:
Anti-HIV Agents - pharmacokinetics
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Child
Drug Monitoring
Ethnic Groups
Female
HIV Infections
Humans
Liver Failure
Male
Medical sciences
Patient Compliance
Pharmacology. Drug treatments
Pregnancy
Protein Binding
Sex Factors
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors and protease inhibitors provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met in Rome, Italy. This followed an inaugural meeting in Perugia, Italy, in October 2000, which resulted in the article published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review the questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. This report, which has been updated to include material published or presented at international conferences up to the end of September 2004, reviews pharmacokinetic and pharmacodynamic data and reports the issues discussed by the panel, offering advice to clinical care providers who may be currently, or are considering incorporating TDM into the routine care of their patients. In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials.
ISSN:1359-6535
2040-2058
DOI:10.1177/135965350501000307